Longer TB prevention pill cuts risk in HIV patients

NCT ID NCT00164281

Completed Prevention Sponsor: Centers for Disease Control and Prevention Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking the tuberculosis prevention drug isoniazid for 36 months instead of the usual 6 months could better prevent TB in adults with HIV. Nearly 2,000 participants in Botswana were randomly assigned to either short or long treatment. The goal was to see if longer therapy reduces new TB cases and deaths.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isoniazid
What this could lead to: If successful, this could show that extending isoniazid preventive therapy beyond 6 months reduces tuberculosis cases in people with HIV.
What could go wrong: This is a completed Phase 4 trial, so results are already known. However, the benefit may not apply to all populations or settings, and isoniazid can cause liver side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease tuberculosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS TUBERCULOSIS

Contacts and locations

Locations

Gaborone and Francistown Health Clinics

Gaborone, Botswana

More trials for these conditions

Other studies related to the condition(s) this trial covers.